The study conducted to know the use of Silvernova skin cream in patients with selected skin diseases.

An Open labeled Multicentric Pilot study to study the safety and efficacy of Silvernova skin cream (20 ppm) in ambulant patients with selected skin diseases

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030388

Enrollment

Registered

2021-01-11

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Silvernova Skin Cream: Colloidal Silver 20 PPM applied on skin (local application) for 14 day Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and female aged 18 to 65 who are suffering from mild or moderate fungal infection like intertrigo, tinea, bullous skin disorders like pemphigus or pemphigoids and intense skin care and repair post cosmetic skin procedures including laser procedures, peels. Based on appearance of lesions, Investigators will have the judgement on fungal infection being mild, moderate, or severe. 2.Willing to give informed consent

Exclusion criteria

Exclusion criteria: 1.Patients who are suffering from any major systemic illnesses. 2.Patients Participation in any other clinical trials evaluating investigational pharmaceuticals orbiologics within 3 months or devices within 30 days of admission to the study. 3.Cases with secondary infections will be excluded from this study. 4.Severe cases of fungal infection.

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and efficacy of Silvernova skin cream local application as an adjuvant in patients with mild to moderate cases of selected skin diseases.Timepoint: 14 days	—

Secondary

Measure	Time frame
Tolerability in patients applying Silvernova skin creamTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr Shashank Jadhav

Viridis BioPharma Pvt Ltd

shashank@viridisbiopharma.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026